Clinical Research

National University of Ireland Galway

Ulcerative Colitis

Plasma Cell Cancer

Mantle-Cell Lymphoma

Crohn Disease

Ulcer

Autism Spectrum Disorder

Non-Hodgkin Lymphoma

Colitis

Lymphoma

Multiple Myeloma

Bendamustine

Vedolizumab

Zanubrutinib

Dexamethasone

Takeda

National University of Ireland, Galway, Ireland

BeiGene

Mass General Brigham

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

National University of Ireland Galway | Clinical Research

Site insights

Work at this site?

Active trials

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Trial sponsors